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Abstract: Polycystic ovary syndrome (PCOS) is an endocrine condition associated with
reproductive and psychiatric disorders, and with obesity. Eating disorders, such as bulimia
and recurrent dieting, are also linked to PCOS. They can lead to the epigenetic dysregulation
of the hypothalamic–pituitary–gonadal (HPG) axis, thereby impacting on ovarian folliculogenesis.
We postulate that PCOS is induced by psychological distress and episodes of overeating and/or
dieting during puberty and adolescence, when body dissatisfaction and emotional distress are often
present. We propose that upregulated activation of the central HPG axis during this period can be
epigenetically altered by psychological stressors and by bulimia/recurrent dieting, which are common
during adolescence and which can lead to PCOS. This hypothesis is based on events that occur during
a largely neglected stage of female reproductive development. To date, most research into the origins
of PCOS has focused on the prenatal induction of this disorder, particularly in utero androgenization
and the role of anti-Müllerian hormone. Establishing causality in our peripubertal model requires
prospective cohort studies from infancy. Mechanistic studies should consider the role of the gut
microbiota in addition to the epigenetic regulation of (neuro) hormones. Finally, clinicians should
consider the importance of underlying chronic psychological distress and eating disorders in PCOS.
Keywords: PCOS; emotional disturbance; psychological stress; nutrition; eating disorders;
DNA methylation; prevention; neuroendocrine hormones
1. Introduction
Polycystic ovary syndrome (PCOS) is the most common disorder in women during the reproductive
period, accounting for around 80% of anovulatory subfertility [1]. Obesity, early features
of cardiometabolic diseases, including insulin resistance and hyperinsulinemia, and a range of mental
illnesses are also associated with PCOS [2–5]. The estimated prevalence of PCOS in women
of reproductive age ranges between 9% and 18%, with the highest prevalence in Western countries [5–7].
Variations in these rates have mainly been attributed to the use of different diagnostic criteria. PCOS is,
by definition, a normo-gonadotropic, normo-estrogenic state and is often associated with anovulation.
PCOS is diagnosed according to the Rotterdam 2003 consensus with typical features including clinical
Int. J. Mol. Sci. 2020, 21, 8211; doi:10.3390/ijms21218211 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 8211 2 of 20
or biochemical hyperandrogenism, irregular menstrual cycles and the so-called polycystic ovarian
morphology [8]. The diagnostic criteria for PCOS, particularly during adolescence, are controversial
because many features used in adult women, such as acne, irregular menses and polycystic ovary
morphology (PCOM), can be normal physiological characteristics of puberty [9].
Although PCOS presents in numerous women during adolescence, coincident with pubertal
activation of the hypothalamic–pituitary–gonadal (HPG) axis, it can affect women at any stage during
the life course. Signs of precocious pubarche and adolescent hyperandrogenism with or without
obesity, and insulin resistance may indicate the early stages of PCOS [10]. PCOS has long been
considered a primary syndrome of ovarian dysfunction. However, recent evidence has started to
shed light on neuroendocrine impairments associated with the pathophysiology of this syndrome [11].
In women with PCOS, the function of the gonadotropin-releasing hormone (GnRH) pulse generator is
perturbed, giving rise to luteinizing hormone (LH) overproduction and a relative follicle-stimulating
hormone (FSH) shortage. This over-secretion of LH further increases androgen production by the theca
cells surrounding the follicle. Historically, this has been attributed to a lack of negative feedback
from progesterone as a result of hypothalamic prenatal androgenization [11]. In women with PCOS,
anti-Müllerian hormone (AMH) serum levels are also frequently found to be 2- to 3-fold higher
than in women with healthy ovaries. Moreover, the severity of the PCOS phenotype correlates with
AMH production, which is higher in anovulatory than in ovulatory PCOS patients [12].
Although overproduction of AMH is central to our understanding of the pathophysiology
of PCOS, we propose a novel and complementary hypothesis that considers PCOS as an adverse
psychological condition which develops in women at the onset of puberty and throughout adolescence
as a consequence of stress, mood problems and low self-esteem, together with metabolic disturbances
arising from eating disorders, which constitute a secondary confounder (Figure 1). Furthermore,
we propose that intrauterine exposure to psychological distress and to the eating disorder pathology,
in part mediated by AMH, can predispose offspring to PCOS. We further consider that this is particularly
so in mothers who may themselves be polycystic, or who had endured periods of psychological stress
perhaps leading to the onset of eating disorders during adolescence.
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Figure 1. The impact of alternating recurrent periods of psychological stressors and eating disorders
in the critical periods during the life course in the developmental origins of polycystic ovary syndrome
(PCOS). Modified from Steegers et al.’s Textbook of Obstetrics and Gynaecology; a life course
approach, 2019 [13].
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2. Linking Psychological Distress and Eating Disorders to PCOS
Women of reproductive age with PCOS are more often affected by mild to moderate psychiatric
disorders, such as mood and eating disorders [2,14–16]. Whilst most studies investigating these
associations have been of a cross-sectional design, one of the few longitudinal studies undertaken
indicated that, among women with PCOS, around 20% developed a depressive disorder within
two years [17]. Several underlying psychological and neuroendocrine pathways could explain
this observation. Firstly, accompanying symptoms, such as menstrual irregularity and subfertility,
can contribute to psychological distress, eventually resulting in a psychiatric disorder [8]. Similarly,
changes in appearance like weight gain, acne and scalp hair thinning may contribute to alterations
in body image and a diminished self-esteem. However, these physical symptoms do not seem to
fully account for the emotional disturbances experienced by PCOS patients [18], indicating that other
mechanisms are also involved.
Mood and eating disorders are among the most common psychiatric disorders observed in women
with PCOS and most likely the result of complex interactions between biological, sociocultural,
familial and individual factors. The proposed diathesis–stress model of psychopathology suggests
that a (biological) vulnerability for a mental illness is only expressed when it is triggered by a certain
degree of stress. Indeed, stress is an important trigger for both depression and eating disorders.
In bulimia nervosa and binge eating disorder, binge eating may occur as a coping mechanism for stress,
as it brings temporary relief. Moreover, stress has also been associated with poor self-esteem and body
image dissatisfaction [19], core symptoms of mood and eating disorders. Stressors may also affect
health and well-being through neuroendocrine impairments. Stressful events lead to the production
of several hormones (cortisol, epinephrine and norepinephrine) associated with the fight-or-flight
response. While historically essential to survive, chronic elevated levels of stress-related hormones
are detrimental for health and potentially play a causal role in the derangement of neuroendocrine
pathways, exacerbating the development of PCOS. Although the full etiology of most psychiatric
disorders has yet to be elucidated, impairments of neuroendocrine pathways associated with PCOS are
also common features of associated psychiatric disorders. In both depression and anxiety, for example,
serotonin imbalances and high basal cortisol levels are often observed [20]. Elevated testosterone
concentrations may also promote food cravings, perhaps via a poor impulse control [21], which provides
an explanation for the link between eating disorders and PCOS. Finally, psychological stress may also
interfere with serum AMH levels, as discussed later, illustrated by the high levels of stress that have
been related to decreased levels of AMH in subfertile women [22].
Given that most studies on PCOS and psychiatric disorders were of a cross-sectional design,
the direction of effect in this association remains to be determined [14,15]. Whilst Kerchner et al. [17]
described new cases of depression after the onset of PCOS in their longitudinal study, it was unclear
whether these cases already had high sub-clinical levels of depressive symptoms when PCOS was
diagnosed. Although several plausible arguments suggest that PCOS contributes to the development
of psychiatric disorders, both conditions may also be expressions of the same underlying pathways.
Yet, the alternative hypothesis in which physiological stressors associated with psychiatric disorders
cause PCOS is also likely.
2.1. Eating Disorders and Impaired Neuroendocrine Pathways in PCOS
Eating disorders disturb neuroendocrine pathways leading to altered biochemical processes.
Recurrent binge eating can increase insulin levels, by decreasing concentrations of sex hormone-binding
globulin that can increase free circulating testosterone [23], thereby negatively impacting follicular
maturation and ovulation [24]. More generally, stress also increases insulin levels which contribute
to the development of PCOS by similar routes [25]. Another pathway relates to the reward system
in the brain, which is involved in the regulation of binge eating and food cravings. Craved and
binged foods are usually high in fat and/or sugar, resulting in a satisfied feeling due to the activation
of dopamine neurons in the reward pathway. Yet, increased energy intake also promotes weight gain
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and increases insulin levels. Elevated insulin levels in turn stimulate ovarian androgen production,
thereby contributing to a vicious circle of androgens and obesity [26].
Activation of the hypothalamic–pituitary–adrenal axis in response to psychological stress results
in continuous secretion of cortisol. In particular, binge eating is correlated with high cortisol levels [27].
As mentioned before, the primary trigger during binge eating is stress, which repeatedly activates
the adrenal cortex for cortisol secretion. This consistent stimulation could explain the increase in cortisol
levels observed in PCOS women [28].
Obesity, which is common in, but not exclusive to, binge eating disorders, can disrupt normal
appetite signaling regulated by leptin and ghrelin, two important hormones controlling hunger and
satiety. Diet-induced obesity in rodents, who were given high doses of leptin (an appetite suppressor),
reduced food intake, but this effect lasted only around two weeks. It seems that the rodents
developed hypothalamic leptin resistance [29], which can lead to leptin overproduction. Leptin also
has a reproductive function, acting at many levels within the hypothalamic–pituitary–ovarian axis.
In particular, it has been suggested that the leptin receptors in the ovary among some obese patients
may be overexposed to leptin, which in turn may affect ovarian function [30].
The circulating gut hormone ghrelin (acylated ghrelin, AG) regulates appetite and increases
food intake and adiposity [31]. However, ghrelin has also been shown to interact with the brain
reward pathways as it promotes the rewarding aspect of a high-fat diet in rodents [32,33]. Rodents fed
ad libitum developed robust binge eating behaviors when fed high-fat diets. This intermittent access
to palatable food induces hyperphagia in satiated mice [34]. Importantly, mice lacking the ghrelin
receptor Gshr1 are resistant to binge eating and consume less calories [35]. These findings highlight
the crucial role of ghrelin signaling in the development of altered eating behavior and food preference.
The natural occurring antagonist of ghrelin, unacylated ghrelin (UAG), inhibits ghrelin action [31]
and the AG/UAG ratio in patients with hyperphagia is elevated [36]. Furthermore, treatment with
UAG analogs prevents diet-induced obesity in mice [37]. Hence, UAG may be a new treatment option
for PCOS to break the vicious circle of androgen excess and obesity.
In addition, reduced serotonin levels are reported in the serum of PCOS women [38], which inhibit
the pulsatile release of GnRH/LH [39]. Eating disorders have been linked to genes that are involved
in the regulation of the neurotransmitter serotonin [40], which modulates both appetite, mood
and circadian rhythm. Research showed that patients with anorexia nervosa (AN) had low levels
of 5-hydroxyindolacetic acid (5-HIAA), which is indicative of low serotonin levels. This may be
the result of the restricted food intake, as serotonin is made from tryptophan which is an essential
nutrient. However, after recovery, these women showed higher levels of 5-HIAA than healthy
women. A suggested explanation for this somewhat counterintuitive finding is that AN is caused
by abnormalities in the serotonin system, in particular by serotonin overactivity in different brain areas.
Yet, a reversed mechanism may be at play as well, with AN causing an overdrive of the serotonin
system, in response to the previous shortage of serotonin.
2.2. Eating Disorders, Gut Microbiota and Intermediary Metabolism
Although detailed consideration is beyond the scope of the current article, there is an increasing
body of evidence to implicate the gut microbiota in the etiology and progression of eating disorders,
together with a broad range of related psychiatric conditions, obesity and the establishment of metabolic
disease (including insulin resistance) and PCOS [41–43]. The composition of the gut microbiome
can influence the absorption of various metabolites, such as short-chain fatty acids, bile acids and
amino acids, together with inflammatory mediators (e.g., Interleukin-22) [44], the aforementioned
gut-brain peptides (e.g., ghrelin and glucagon-like peptide 1 [GLP1]) and various neuromodulators
(e.g., γ-amino butyric acid [GABA]) involved in mood regulation (41). Each of these metabolites
can independently or collectively act on neuroendocrine pathways to induce a state of insulin
resistance and hyperandrogenism, which in turn can predispose to PCOS [45]. Indeed, a recent
cross-sectional study of Chinese obese and non-obese women with PCOS revealed significant
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enrichment in microbiota with active one-carbon (1C) and closely related purine and pyrimidine
metabolic pathways, as well as enhanced tricarboxylic acid and lipopolysaccharide metabolic
activities [45]. Inhabiting a unique niche at the point of intestinal absorption, gut microbes exhibiting
these features will have undoubtedly contributed to the altered metabolic and endocrine characteristics
of PCOS women in these study populations.
Lam et al. [41] explained that food restriction and limited food choices, both associated with eating
disorders and obesity, can modify the gut microbiota and generally lead to a reduction in diversity
associated with poor clinical outcomes. Gut microbes are also responsive to maternal (eukaryotic)
hormonal signals, including neurohormones (e.g., norepinephrine, serotonin) that can be modified
during psychological stress [45].
2.3. Eating Disorders and Diet Composition
Nutritional status is very clearly implicated in the (patho) physiology and treatment of PCOS.
Interestingly, androgens stimulate appetite, food craving and recurrent binge eating, although
the underlying mechanisms are not understood [21,46,47]. In an explorative study, we observed that
women with PCOS were frequently dieting, very often consuming substandard foodstuffs relative to
that consumed by the control population [48]. These substandard diets were characterized by low
serum folate and elevated homocysteine concentrations, indicating a more general derangement
in 1C metabolism associated with a hyperandrogenic status in these women.
Moreover, positive associations were established between an inadequate diet and AMH,
and the free androgen index in PCOS patients. This is consistent with recent findings from
our periconception cohort demonstrating that strong adherence to a healthy dietary pattern is
associated with the non-hyperandrogenic PCOS phenotype and lower plasma AMH concentrations [49].
Several other studies have found differences in dietary intake between PCOS patients and healthy
controls [50,51]. In our recent study, we did not observe increased total energy intakes between
hyperandrogenic (HA) and non-HA PCOS patients. This is in contrast to Moran et al. [52], who reported
an overall increase in energy intake, with improved diet quality, in PCOS patients. Furthermore,
PCOS women were more likely to consume a Mediterranean dietary pattern [53]. This finding could be
the consequence of adopting a healthy dietary pattern after having been diagnosed with PCOS. Dietary
interventions that, for example, involve intermittent periods of fasting [54] and/or the use of insulin
sensitizers (e.g., inositol isoforms) [55], can lead to improvements of PCOS features, substantiating
the hypothesis that diet can indeed affect neuroendocrine pathways that regulate metabolic and
reproductive functions [50,56,57]. Yet, the composition of the ideal weight-loss diet leading to
improved PCOS features, such as hyperandrogenism, cycle regularity and metabolic and psychiatric
outcomes, remains to be elucidated, as study outcomes to date have been conflicting [51,58–63].
Such diets vary in the content of carbohydrates, proteins and fat, or some combination of these
components. Therefore, in our opinion, weight loss should always be accomplished by adequate
intakes of healthy foods.
3. The Peripubertal and Adolescent Origin of PCOS
The risk of developing an eating disorder increases around puberty onset and further rises through
adolescence, mediated in part by increasing estrogen levels [64]. Considering the important role
of estrogen in gene transcription, studies suggest that estrogen may be involved in the activation of some
genetic factors that affect eating disorders [65]. We have investigated genetic differences between
women with high or low estrogen levels during puberty, and found that high levels of estrogens were
correlated with substantial genetic effects on disturbed eating [66]. In addition, retrospective studies
have found that precocious puberty onset is related to the prevalence of eating disorders [67] and
psychological stress [68].
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Peripubertal Metabolism, Stress and Eating Disorders
Childhood obesity and excessive nutrient intake are known to independently advance the onset
of puberty in girls [69,70], leading to abnormal (neuro) endocrine activity during adolescence,
which can potentially predispose to PCOS [71]. In general, high dietary intakes of energy, protein
and polyunsaturated fatty acids are associated with early puberty onset, whereas high-fiber and
monounsaturated fatty acid diets are associated with later menarche onset. Furthermore, the incidence
of eating disorders in girls with PCOS is increased in overweight and obese subjects [72], which, in turn,
may serve to further exacerbate the condition (Figure 2).
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periods; see Figure 1), and/or by eating disorders and the gut microbiome (see Figure 2). This in turn
can alter the availability of various intermediary metabolites that serve as substrates and co-factors
for enzymes involved in chromatin modification (Histone acetyltransferases (HAT) and Histone
deacetylases (HDAC; e.g., Sirtuins), Histone methyl transferase (HMT) and DNA methyltransferases
(DNMTs), Histone (lysine) (KDM) and Ten-Eleven Translocation (TET) demethylases) [80]. Only four
of the better-studied intermediary metabolites (i.e., Acetyl CoA, Nicotin mide adenine dinucleotide
(NAD+), S-adenosylmethio ine (SAM) and alpha-k t glutarate (αKG)) associated with mitochondrial
metabolism are pr sented [81]. Simila ly, the best-studied histone acetylation sites are found on various
lysine (K) residues on histones H3 a d H4, although they also occur on H2A and H2B. Examples
of histone (lysine) (mono-[me1], di-[me2] and tri-[me3]) are presented, although arginine methylation
should not b discounted [82]. Covalent modifications to DNA include 5-methylcytosine (5mC),
5-formylcytosine (5fC) and 5-hydroxy ethylcytosine (5hmC) which are carefully choreographed
with histone acetylation/methylation to alter the configuration of chro atin between expressive
and repressive states [83]. The generation of small RNAs that can modify chromatin structure
and alter transcription is not represented. TCA, tricarboxylic-acid cycle; B2, riboflavin; B9, folate;
and B12, cobalamin.
4. The Prenat l Origin of PCOS
Rec nt animal and human studies suggest t t t r i l environment and impaired nutrition
during in utero develop ent play key roles in the development of PCOS [3]. It appears that
AMH acts centrally to exacerbate GnRH- and LH-driven ovarian steroidogenesis, follicular arrest and
overproduction of AMH in the ovary later on in life. During pregnancy, this leads to an AMH-driven
inhibition of aromatase expression in the placenta which, in turn, leads to an increase in testosterone
bioavailability and an overexposure of female offspring to androgens. Indeed, the expression
of genes that regulate serotonin and GABA neurotransmitters involved in emotion regulation and
anxious behavior was altered in the amygdala of offspring from pregnant rats exposed to high levels
of testosterone [84]. There are several animal models that convincingly demonstrate an effect of prenatal
androgenization on the etiology of PCOS linked to offspring anxiety and depression [85]. In addition,
some epidemiologic studies have shown that adolescents with early features of PCOS were more often
born with lower birth weights [86], whilst others found that excess birth weight led to obesity, metabolic
syndrome, precocious puberty onset and PCOS during adolescence [87,88].
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Collectively, these observations are in line with the developmental origins of the health and
disease (DOHaD) paradigm which states that maternal psychological distress and/or poor nutrition
during pregnancy can have long-term detrimental effects on offspring health, predisposing them to
cardio-vascular and metabolic diseases and other disorders in later life. In women with PCOS (F0),
perhaps originating during adolescence, hormonal imbalance during gestation can contribute to
an increased risk of their adolescent children (F1) developing a broad spectrum of psychological
disorders (including anxiety and eating disorders [89,90]), together with PCOS [86] (Figures 1 and 2).
As stated earlier, prenatal exposure to androgens, testosterone or dihydrotestosterone generates
the closest PCOS-like phenotype in a variety of animal models [11]. Indeed, it was recently shown
that AMH levels in pregnant women with PCOS are around two times higher compared to healthy
pregnant controls. Moreover, they were still elevated during the third trimester of pregnancy, a period
during which the female fetus is sensitive to androgenization [91].
4.1. Anti-Müllerian Hormone
AMH is secreted by primary and growing small antral follicles and inhibits further follicular
recruitment from the primordial follicle pool. AMH is also important in attenuating follicular
sensitivity to cyclical FSH action, leading to the selection of the dominant follicle [92], and decreasing
aromatase activity and the number of luteinizing hormone/choriogonadotropin receptors (LHCGR)
in these cells [93]. Mature neurons in the adult brain express high levels of AMH receptors
type II (AMHR2) in both sexes. AMHR2 is expressed in a significant subset of hypothalamic
GnRH neurons in both mice and humans, and also in different brain areas and cell types involved
in the central control of reproduction. These include the organum vasculosum laminae terminalis
(OVLT) of the hypothalamus and the median eminence. Within the median eminence, AMHR2 is
expressed by endothelial cells, tanycytes and the majority of arcuate nucleus neurons. Fenestrated
endothelial cells and tanycytes regulate GnRH secretion by interacting closely with GnRH terminals
in the median eminence [94]. Moreover, stimulation of GnRH neurons with AMH (both in vitro and
in vivo) leads to increased firing frequency of GnRH neurons, resulting in LH over-secretion and
a relative under-excretion of FSH form the pituitary [95].
Recently, it has been shown that AMH is expressed in migratory GnRH neurons in both mice and
humans during embryonic development. AMH thus serves as a pro-motility factor for GnRH neurons.
Pathohistological analysis of Amhr2-deficient mice showed abnormal development of the peripheral
olfactory system and defective embryonic migration of neuroendocrine GnRH cells to the basal
forebrain, which results in reduced fertility in adults [96]. Furthermore, studies with pregnant mice
found that intrauterine treatment with high concentrations of AMH led to the production of offspring
that exhibited typical features of PCOS, such as hyperandrogenism in combination with increased
LH pulses. In such circumstances, female offspring had fewer ovulations [97].
Taken together, it appears that AMH acts centrally to exacerbate GnRH- and LH-driven ovarian
steroidogenesis, follicular arrest and overproduction of AMH in the ovary later on in life. During
pregnancy, this leads to an AMH-driven inhibition of aromatase expression in the placenta which,
in turn, leads to an increase in testosterone bioavailability and an overexposure of female offspring to
androgens. This is known to be associated with the PCOS phenotype. Indeed, in humans, AMH has
been shown to modify the enzymatic activity of steroid hormone synthesis, and women with PCOS have
been reported to have reduced placental aromatase activity and increased steroidogenic activity [98].
These data are strongly supported by the group of Giacobini in humans as well as in animal models,
indicating a crucial role for AMH in the pathogenesis of PCOS [99,100].
4.2. Prenatal Metabolism and Stress
Women with mood, anxiety and eating disorders are at increased risk of pregnancy complications
associated with adverse maternal and perinatal outcomes [101,102]. Among these complications is
hyperemesis gravidarum leading to dehydration, electrolyte imbalance and malnutrition. Whilst
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relatively rare (<1% pregnancies), this condition can, together with nausea and vomiting (50–90%
of all pregnancies), lead to temporal imbalances in key water-soluble nutrients such as B vitamins
(Figure 3), with potential longer-term consequences for fetal development and offspring health
including (neuro)endocrine disorders leading to PCOS. Of greater importance is the prevalence
of gestational diabetes in women with PCOS which, at around 40%, is 3- to 5-fold higher than that
of healthy women [103]. Adipocyte function in adult (~30 years) offspring from such pregnancies
is epigenetically modified (discussed later) in such a way as to possibly predispose individuals
to metabolic syndrome [104] leading to PCOS. Further, there is now compelling evidence to link
exposure to a hyperandrogenic intra-uterine environment with PCOS during offspring adult life [105].
A sequelae to such exposure is adipose tissue dysfunction in adulthood, which is implicated in
the pathophysiology of PCOS. It was recently demonstrated, in a prenatally androgenized sheep
model of PCOS, that adipogenesis is impaired in subcutaneous tissues during adolescence only to
undergo compensatory hypertrophy during adulthood, paralleled with an overexpression of various
inflammatory mediators in concert with dyslipidemia indicators of visceral fat accumulation [106].
Finally, thrombophilia and recurrent pregnancy loss are more extreme features of PCOS prevalent
across different ethnic populations and highly correlated with genetic variants in specific folate cycle
enzymes (Figure 3), plasma concentrations of tHcy, testosterone and measures of insulin resistance
and obesity [107–110].
4.3. Prenatal Stress and the Microbiota
Perinatal mood and anxiety disorders (PMAD), arising in part due to fluctuating levels of gonadal
steroids, represent a broad category of psychological conditions that typically affect around 10–20%
of women. PMAD are known to unfavorably alter the vaginal microbiota [42], which is important
given that, in eutherian mammals, microbial symbionts which may be present in utero [111] are known
to be transmitted to offspring during transit through the birth canal, and subsequently via breast
milk and by maternal contact [112,113]. They are thus subject to modification by factors such as
pregnancy-related anxiety, which has been found to unfavorably alter the composition of microbiota
isolated from newborn meconium and infant stool [114,115], with potential longer-term implications
for cardio-vascular and metabolic health and PCOS.
Extending beyond the mode of delivery (i.e., vaginal delivery vs. caesarian section), at parturition,
microbial colonization during the early period of infancy is also influenced by the nature of feeding
(i.e., breast vs. formula milk). Whilst data on long-term health implications of such interventions are
emerging from studies in both neonatal humans and animals, the focus to date has primarily centered
on the development of allergies and metabolic disorders including obesity in offspring [116], with little
consideration given to psychiatric conditions and reproductive disorders, such as PCOS, that may also
originate during this period.
5. Epigenetic Basis of PCOS
An increasing body of data from both human and animal studies has emerged in recent years
that describes the epigenetic basis for the developmental origins of PCOS. From epigenome-wide
association studies (EWAS) in humans, a series of functional pathways (linked to metabolic and
psychiatric comorbidities, as well as autoimmune diseases (e.g., type I diabetes)) have been identified
that are consistent across a broad range of cell/tissue types from individuals of diverse geographical
origin and ethnic background [117]. These observations indicate common underlying signaling
networks involved both in the etiology and heterogeneity of PCOS including pathways linked to
mitochondrial metabolism [118]. It is important to note that underlying epigenetic mechanisms extend
beyond covalent modifications to histones and DNA depicted in Figure 3 to include interacting long
non-coding and microRNAs that are known to influence DNA methylation in PCOS [119]. These
are also metabolically regulated [80] and are associated with insulin resistance and lipid disorders
in PCOS women [120]. However, evidence for their direct actions in PCOS is limited [121] and this,
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together with the diverse variety of RNA species and mechanisms of biogenesis, prohibits extensive
consideration in this article.
5.1. Peripubertal Diet, Epigenetics and PCOS
The methylation status of several growth-related and sex steroid genes (e.g., IGF2, CYP19A1 and
HSD11B2) is influenced by diet and can affect the timing of puberty onset in adolescent girls [122,123].
A wider role for genomic imprinting in the timing of puberty onset has recently attracted attention given
that mutations in at least two imprinted genes (i.e., Makorin Ring Finger Protein 3 (MKRN3) and Delta-like
noncanonical Notch ligand 1 (DLK1)) lead to precocious puberty onset in girls [124]. Mutations in genes
encoding kisspeptin (KISS1) and its receptor (KISS1R) (both activators GnRH secretion) can also advance
the onset of puberty. Together with neurokinin B and dynorphin, kisspeptin is produced by a complex
of neurons, referred to as KDNy neurons, located in the arcuate nucleus of the hypothalamus and which
regulate GnRH secretion. KNDy neurons are subject to epigenetic control and can be modified by a group
of energy-sensing proteins called sirtuins, which are tightly coupled to prevailing levels of the metabolic
factor NAD+ (Figure 3). A recent study with Wister rats demonstrated that the eviction of SIRT1 from
hypothalamic Kiss1 neurons created a permissive chromatin state, the timing of which was accelerated
by overnutrition, thereby advancing puberty onset [125].
A further study in mice offering a diet deficient in folate, methionine and choline (Figure 3) during
their period of adolescence (i.e., 3–6 weeks of age) reported an increase in plasma tHcy concentrations
leading to promotor hypermethylation and loss of expression of Gria1 (encoding Glutamate receptor 1)
in the hippocampus, thus impairing memory learning and fear extinction [126]. Further, key regulatory
sequences of mitochondrial DNA (mtDNA) were hypermethylated in oocytes from polycystic and
hyperhomocysteinemic ovaries of peripubertal pigs, leading to a reduced mtDNA copy number and
transcript expression, together with compromised post-fertilization development [127]. Although not
specifically measured in these two studies, reported derangements in 1C metabolism would have
undoubtedly altered S-adenosylmethionine (SAM)-mediated provision of methyl groups required
for these epigenetic modifications (Figure 3) [128].
Collectively, these studies establish the epigenetic basis for the dietary-mediated timing of puberty
onset and the neuroendocrine regulation of ovarian function in mammals. However, although proposed
as a mechanism underpinning the onset of PCOS in adolescent girls [129], there is currently a lack
of direct evidence supporting the epigenetic basis for PCOS inception during puberty in humans,
and the effects of potential interacting psychiatric comorbidities remain to be explored.
5.2. Prenatal Diet, Epigenetics and PCOS
Our limited understanding of the epigenetic basis for the fetal origins of PCOS is based primarily
on work undertaken in animal models, such as rodents, sheep and non-human primates. These studies have
assessed the effects of maternal diet/metabolism during pregnancy, modeled the consequences of prenatal
androgenization and investigated the outcome of in utero exposure to environmental chemicals [130–132].
In the case of prenatal androgenization, treatment exposures have generally been undertaken
during early/mid-gestation, reflecting a key stage of androgen-sensitive gonadal development
across species [132]. By way of example, prenatal androgenization in rats led to genome-wide
alterations in DNA methylation in the ovaries of adult female offspring reflecting a variety of gene
networks associated with adult PCOS [133]. Similarly, prenatal androgen exposure in sheep led to
upregulation of H3K9me3 (gene repressive), and H3K27ac and H3K9ac (both gene activating) marks
in the ovaries of adult offspring, affecting genes involved in steroid biosynthesis and inflammation [134].
In a separate study undertaken in mice, blood concentrations of the methyl donor SAM were reduced
in prenatally androgenized offspring in line with attenuated ovarian expression of both Mtr and
Bhmt (two 1C cycle enzymes involved in the remethylation of Hcy to methionine (Figure 3)) [135].
It transpires that the majority of genes encoding 1C enzymes are steroid-responsive, accounting
for differences in expression/activity during both the estrous and menstrual cycles of mammals,
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as well as during pregnancy [128]. Significantly, the reported observations of prenatal androgenization
in mice are consistent with reduced granulosa cell MTR expression and serum SAM concentrations
in hyperandrogenic PCOS women [135].
Evidence from human studies supports the contention that the in utero environment can influence
the genesis of PCOS and related comorbidities. Women diagnosed with PCOS can give rise to children
that exhibit sex-dependent DNA methylation patterns in regulatory regions of various metabolic
and reproductive genes (including adiponectin, AMH and the androgen receptor) associated with
this condition [136,137]. In such studies, however, it is difficult to disentangle the effects of maternal
genotype. Therefore, analyzing data from a large Swedish nationwide register-based cohort study,
and a case–control study from Chile, Risal et al. [138] initially confirmed that daughters of women
with PCOS are more likely to be diagnosed with PCOS, and then went on to demonstrate that prenatal
androgenization in an inbred strain of mouse led to transgenerational transmission of PCOS up to
at least F3 daughters.
6. Hypothesis and Conclusions
From this background, we postulate that exposure to a variety of psychological stressors
during puberty and adolescence induces chronic psychiatric disorders which, in some individuals,
result in repeated episodes of overeating and dieting, collectively contributing to the development
of PCOS (Figure 2A). Psychological stressors, such as difficulties at school or at home, low self-esteem
or being bullied, are proximal determinants of anxiety, depression and premenstrual dysphoric
disorder that are often observed in young women. We propose that psychological distress and
associated eating disorders during these periods lead to the epigenetic (Figure 3) dysregulation
of (neuro)hormones (e.g., AMH, androgens, estradiol, insulin and ghrelin) involved in the pubertal
upregulation of the HPG axis, which contributes to the development of PCOS and related comorbidities
in these subjects (Figure 2B).
With its primary focus on puberty and adolescence, this hypothesis should be viewed as
an extension, and not a substitute, to current concepts on the developmental origins of PCOS which,
to date, have largely centered on endocrine and metabolic disturbances that occur prenatally. Data
to support the fetal origins of PCOS are compelling, and the central role of AMH and prenatal
androgenization is well established. In women with PCOS (F0; Figure 1), perhaps originating during
adolescence, hormonal/metabolic imbalances during gestation can contribute to an increased risk
of their adolescent children (F1) developing a broad spectrum of psychological conditions (including
anxiety and eating disorders) which, in turn, can enhance their chances of developing PCOS (Figure 2).
Establishing timing and causality in our peripubertal model requires prospective cohort studies from
infancy. Mechanistic studies should consider the role of the gut microbiota and disturbances to
intermediary metabolism, including 1C metabolism, in the epigenetic regulation of (neuro)hormones.
Finally, clinicians should consider the importance of underlying chronic psychological distress and
eating disorders in the etiology of PCOS during both pregnancy and puberty. However, this does not
preclude clinicians from implementing dietary assessment and evidence-based behavioral interventions
as part of preconception and reproductive care (e.g., www.smarterpregnancy.co.uk [139–141]).
In particular, treatment may be warranted in the case of obesity or severe emotional problems,
with cognitive-behavioral therapy, with or without a lifestyle component focused on weight loss,
being most commonly recommended [142].
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factors of overweight and obesity related to diet and disordered eating attitudes in adolescent girls with
clinical features of polycystic ovary syndrome. J. Clin. Med. 2020, 9, 3041. [CrossRef]
73. Eskandari, Z.; Sadrkhanlou, R.-A.; Nejati, V.; Tizro, G. Pcos women show significantly higher homocysteine
level, independent to glucose and e2 level. Int. J. Reprod. Biomed. 2016, 14, 495–500. [CrossRef]
74. Meng, Y.; Chen, X.; Peng, Z.; Liu, X.; Sun, Y.; Dai, S. Association between high serum homocysteine levels
and biochemical characteristics in women with polycystic ovarian syndrome: A systematic review and
meta-analysis. PLoS ONE 2016, 11, e0157389. [CrossRef]
75. Must, A.; Jacques, P.F.; Rogers, G.; Rosenberg, I.H.; Selhub, J. Serum total homocysteine concentrations
in children and adolescents: Results from the third national health and nutrition examination survey
(nhanes iii). J. Nutr. 2003, 133, 2643–2649. [CrossRef]
76. Chung, K.H.; Chiou, H.Y.; Chen, Y.H. Associations between serum homocysteine levels and anxiety and
depression among children and adolescents in taiwan. Sci. Rep. 2017, 7, 8330. [CrossRef] [PubMed]
77. Esnafoglu, E.; Ozturan, D.D. The relationship of severity of depression with homocysteine, folate, vitamin b12,
and vitamin d levels in children and adolescents. Child Adolesc. Ment. Health 2020. [CrossRef]
78. Loria-Kohen, V.; Gómez-Candela, C.; Palma-Milla, S.; Amador-Sastre, B.; Hernanz, A.; Bermejo, L.M. A pilot
study of folic acid supplementation for improving homocysteine levels, cognitive and depressive status
in eating disorders. Nutr. Hosp. 2013, 28, 807–815.
Int. J. Mol. Sci. 2020, 21, 8211 17 of 20
79. Schiuma, N.; Costantino, A.; Bartolotti, T.; Dattilo, M.; Bini, V.; Aglietti, M.C.; Renga, M.; Favilli, A.; Falorni, A.;
Gerli, S. Micronutrients in support to the one carbon cycle for the modulation of blood fasting homocysteine
in pcos women. J. Endocrinol. Investig. 2020, 43, 779–786. [CrossRef]
80. Sharma, U.; Rando, O.J. Metabolic inputs into the epigenome. Cell Metab. 2017, 25, 544–558. [CrossRef]
[PubMed]
81. Wiese, M.; Bannister, A.J. Two genomes, one cell: Mitochondrial-nuclear coordination via epigenetic
pathways. Mol. Metab. 2020, 38, 100942. [CrossRef]
82. Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21, 381–395.
[CrossRef]
83. Patel, D. A structural perspective on readout of epigenetic histone and DNA methylation marks. Cold Spring
Harb. Perspect. Biol. 2016, 8, a018754. [CrossRef]
84. Hu, M.; Richard, J.E.; Maliqueo, M.; Kokosar, M.; Fornes, R.; Benrick, A.; Jansson, T.; Ohlsson, C.; Wu, X.;
Skibicka, K.P.; et al. Maternal testosterone exposure increases anxiety-like behavior and impacts the limbic
system in the offspring. Proc. Natl. Acad. Sci. USA 2015, 112, 14348–14353. [CrossRef]
85. Stener-Victorin, E.; Padmanabhan, V.; Walters, K.A.; Campbell, R.E.; Benrick, A.; Giacobini, P.; Dumesic, D.A.;
Abbott, D.H. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome.
Endocr. Rev. 2020, 41, 538–576. [CrossRef]
86. Sir-Petermann, T.; Hitchsfeld, C.; Maliqueo, M.; Codner, E.; Echiburú, B.; Gazitúa, R.; Recabarren, S.;
Cassorla, F. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum. Reprod. 2005, 20,
2122–2126. [CrossRef]
87. Nicandri, K.F.; Hoeger, K. Diagnosis and treatment of polycystic ovarian syndrome in adolescents. Curr. Opin.
Endocrinol. Diabetes Obes. 2012, 19, 497–504. [CrossRef]
88. Qiao, Y.; Ma, J.; Wang, Y.; Li, W.; Katzmarzyk, P.T.; Chaput, J.P.; Fogelholm, M.; Johnson, W.D.; Kuriyan, R.;
Kurpad, A.; et al. Birth weight and childhood obesity: A 12-country study. Int. J. Obes. Suppl. 2015, 5,
S74–S79. [CrossRef]
89. Robinson, S.L.; Ghassabian, A.; Sundaram, R.; Trinh, M.H.; Bell, E.M.; Mendola, P.; Yeung, E.H.
The associations of maternal polycystic ovary syndrome and hirsutism with behavioral problems in offspring.
Fertil. Steril. 2020, 113, 435–443. [CrossRef] [PubMed]
90. Chen, X.; Kong, L.; Piltonen, T.T.; Gissler, M.; Lavebratt, C. Association of polycystic ovary syndrome
or anovulatory infertility with offspring psychiatric and mild neurodevelopmental disorders: A finnish
population-based cohort study. Hum. Reprod. 2020, 35, 2336–2347. [CrossRef]
91. Piltonen, T.T.; Giacobini, P.; Edvinsson, Å.; Hustad, S.; Lager, S.; Morin-Papunen, L.; Tapanainen, J.S.;
Sundström-Poromaa, I.; Arffman, R.K. Circulating antimüllerian hormone and steroid hormone levels
remain high in pregnant women with polycystic ovary syndrome at term. Fertil. Steril. 2019, 111, 588–596.
[CrossRef]
92. Durlinger, A.L.; Gruijters, M.J.; Kramer, P.; Karels, B.; Kumar, T.R.; Matzuk, M.M.; Rose, U.M.; de Jong, F.H.;
Uilenbroek, J.T.; Grootegoed, J.A.; et al. Anti-müllerian hormone attenuates the effects of fsh on follicle
development in the mouse ovary. Endocrinology 2001, 142, 4891–4899. [CrossRef]
93. Dumesic, D.A.; Lesnick, T.G.; Stassart, J.P.; Ball, G.D.; Wong, A.; Abbott, D.H. Intrafollicular antimüllerian
hormone levels predict follicle responsiveness to follicle-stimulating hormone (fsh) in normoandrogenic
ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human fsh therapy
for in vitro fertilization and embryo transfer. Fertil. Steril. 2009, 92, 217–221.
94. Prevot, V.; Dehouck, B.; Sharif, A.; Ciofi, P.; Giacobini, P.; Clasadonte, J. The versatile tanycyte: A hypothalamic
integrator of reproduction and energy metabolism. Endocr. Rev. 2018, 39, 333–368. [CrossRef] [PubMed]
95. Cimino, I.; Casoni, F.; Liu, X.; Messina, A.; Parkash, J.; Jamin, S.P.; Catteau-Jonard, S.; Collier, F.; Baroncini, M.;
Dewailly, D.; et al. Novel role for anti-müllerian hormone in the regulation of gnrh neuron excitability and
hormone secretion. Nat. Commun. 2016, 7, 10055. [CrossRef] [PubMed]
96. Malone, S.A.; Papadakis, G.E.; Messina, A.; Mimouni, N.E.H.; Trova, S.; Imbernon, M.; Allet, C.; Cimino, I.;
Acierno, J.; Cassatella, D.; et al. Defective amh signaling disrupts gnrh neuron development and function
and contributes to hypogonadotropic hypogonadism. eLife 2019, 8, e47198. [CrossRef]
97. Tata, B.; Mimouni, N.E.H.; Barbotin, A.L.; Malone, S.A.; Loyens, A.; Pigny, P.; Dewailly, D.; Catteau-Jonard, S.;
Sundström-Poromaa, I.; Piltonen, T.T.; et al. Elevated prenatal anti-müllerian hormone reprograms the fetus
and induces polycystic ovary syndrome in adulthood. Nat. Med. 2018, 24, 834–846. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 8211 18 of 20
98. Cook, C.L.; Siow, Y.; Brenner, A.G.; Fallat, M.E. Relationship between serum müllerian-inhibiting substance
and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.
Fertil. Steril. 2002, 77, 141–146. [CrossRef]
99. Barbotin, A.L.; Peigné, M.; Malone, S.A.; Giacobini, P. Emerging roles of anti-müllerian hormone
in hypothalamic-pituitary function. Neuroendocrinology 2019, 109, 218–229. [CrossRef]
100. Silva, M.S.B.; Giacobini, P. New insights into anti-müllerian hormone role in the hypothalamic-pituitary-gonadal
axis and neuroendocrine development. Cell Mol. Life Sci. 2020, 1–16. [CrossRef]
101. Alder, J.; Fink, N.; Bitzer, J.; Hösli, I.; Holzgreve, W. Depression and anxiety during pregnancy: A risk factor
for obstetric, fetal and neonatal outcome? A critical review of the literature. J. Matern Fetal Neonatal Med.
2007, 20, 189–209. [CrossRef]
102. Hoirisch-Clapauch, S.; Brenner, B.; Nardi, A.E. Adverse obstetric and neonatal outcomes in women with
mental disorders. Thromb. Res. 2015, 135 (Suppl. 1), S60–S63. [CrossRef]
103. Dumesic, D.A.; Hoyos, L.R.; Chazenbalk, G.D.; Naik, R.; Padmanabhan, V.; Abbott, D.H. Mechanisms
of intergenerational transmission of polycystic ovary syndrome. Reproduction 2020, 159, R1–R13. [CrossRef]
104. Hansen, N.S.; Strasko, K.S.; Hjort, L.; Kelstrup, L.; Houshmand-Øregaard, A.; Schrölkamp, M.; Schultz, H.S.;
Scheele, C.; Pedersen, B.K.; Ling, C.; et al. Fetal hyperglycemia changes human preadipocyte function
in adult life. J. Clin. Endocrinol. Metab. 2017, 102, 1141–1150. [CrossRef]
105. Filippou, P.; Homburg, R. Is foetal hyperexposure to androgens a cause of pcos? Hum. Reprod. Update 2017,
23, 421–432. [CrossRef]
106. Siemienowicz, K.J.; Coukan, F.; Franks, S.; Rae, M.T.; Duncan, W.C. Aberrant subcutaneous adipogenesis precedes
adult metabolic dysfunction in an ovine model of polycystic ovary syndrome (pcos). Mol. Cell. Endocrinol. 2020,
519, 111042. [CrossRef]
107. Chakraborty, P.; Goswami, S.K.; Rajani, S.; Sharma, S.; Kabir, S.N.; Chakravarty, B.; Jana, K. Recurrent
pregnancy loss in polycystic ovary syndrome: Role of hyperhomocysteinemia and insulin resistance.
PLoS ONE 2013, 8, e64446. [CrossRef]
108. Kazerooni, T.; Ghaffarpasand, F.; Asadi, N.; Dehkhoda, Z.; Dehghankhalili, M.; Kazerooni, Y. Correlation
between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome:
A comparative study. J. Chin. Med. Assoc. 2013, 76, 282–288. [CrossRef]
109. Szafarowska, M.; Segiet, A.; Jerzak, M.M. Methylenotetrahydrololate reductase a1298c and c677t
polymorphisms and adverse pregnancy outcome in women with pcos. Neuro Endocrinol. Lett. 2016,
37, 141–146. [PubMed]
110. Chang, C.L.; Huang, S.Y.; Hsu, Y.C.; Chin, T.H.; Soong, Y.K. The serum level of irisin, but not asprosin,
is abnormal in polycystic ovary syndrome patients. Sci. Rep. 2019, 9, 6447. [CrossRef]
111. Mesa, M.D.; Loureiro, B.; Iglesia, I.; Fernandez Gonzalez, S.; Llurba Olivé, E.; García Algar, O.; Solana, M.J.;
Cabero Perez, M.J.; Sainz, T.; Martinez, L.; et al. The evolving microbiome from pregnancy to early infancy:
A comprehensive review. Nutrients 2020, 12, 133. [CrossRef]
112. Kaplan, J.L.; Shi, H.N.; Walker, W.A. The role of microbes in developmental immunologic programming.
Pediatr. Res. 2011, 69, 465–472. [CrossRef]
113. Kau, A.L.; Ahern, P.P.; Griffin, N.W.; Goodman, A.L.; Gordon, J.I. Human nutrition, the gut microbiome and
the immune system. Nature 2011, 474, 327–336. [CrossRef]
114. Zijlmans, M.A.; Korpela, K.; Riksen-Walraven, J.M.; de Vos, W.M.; de Weerth, C. Maternal prenatal stress is
associated with the infant intestinal microbiota. Psychoneuroendocrinology 2015, 53, 233–245. [CrossRef]
115. Hu, J.; Ly, J.; Zhang, W.; Huang, Y.; Glover, V.; Peter, I.; Hurd, Y.L.; Nomura, Y. Microbiota of newborn
meconium is associated with maternal anxiety experienced during pregnancy. Dev. Psychobiol. 2019, 61,
640–649. [CrossRef]
116. Milani, C.; Duranti, S.; Bottacini, F.; Casey, E.; Turroni, F.; Mahony, J.; Belzer, C.; Delgado Palacio, S.; Arboleya
Montes, S.; Mancabelli, L.; et al. The first microbial colonizers of the human gut: Composition, activities,
and health implications of the infant gut microbiota. Microbiol. Mol. Biol. Rev. 2017, 81, e00036-17. [CrossRef]
117. Tan, Q. Deciphering the DNA methylome of polycystic ovary syndrome. Mol. Diagn. Ther. 2020, 24, 245–250.
[CrossRef]
118. Shukla, P.; Mukherjee, S. Mitochondrial dysfunction: An emerging link in the pathophysiology of polycystic
ovary syndrome. Mitochondrion 2020, 52, 24–39. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8211 19 of 20
119. Mao, Z.; Li, T.; Zhao, H.; Qin, Y.; Wang, X.; Kang, Y. Identification of epigenetic interactions between microrna
and DNA methylation associated with polycystic ovarian syndrome. J. Hum. Genet. 2020. [CrossRef]
120. Abdalla, M.A.; Deshmukh, H.; Atkin, S.; Sathyapalan, T. A review of therapeutic options for managing
the metabolic aspects of polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab. 2020, 11, 2042018820938305.
[CrossRef] [PubMed]
121. Chen, B.; Xu, P.; Wang, J.; Zhang, C. The role of mirna in polycystic ovary syndrome (pcos). Gene 2019, 706,
91–96. [CrossRef]
122. Stueve, T.R.; Wolff, M.S.; Pajak, A.; Teitelbaum, S.L.; Chen, J. Cyp19a1 promoter methylation in saliva
associated with milestones of pubertal timing in urban girls. BMC Pediatr. 2014, 14, 78. [CrossRef] [PubMed]
123. Wu, Y.; Peterson, K.E.; Sánchez, B.N.; Dolinoy, D.C.; Mercado-Garcia, A.; Téllez-Rojo, M.M.; Goodrich, J.M.
Association of blood leukocyte DNA methylation at line-1 and growth-related candidate genes with pubertal
onset and progression. Epigenetics 2018, 13, 1222–1233. [CrossRef]
124. Roberts, S.A.; Kaiser, U.B. Genetics in endocrinology: Genetic etiologies of central precocious puberty and
the role of imprinted genes. Eur. J. Endocrinol. 2020, 183, R107–R117. [CrossRef]
125. Vazquez, A.; Sanchez-Rodriguez, E.; Vargas, F.; Montoro-Molina, S.; Romero, M.; Espejo-Calvo, J.A.;
Vilchez, P.; Jaramillo, S.; Olmo-García, L.; Carrasco-Pancorbo, A.; et al. Cardioprotective effect of a virgin
olive oil enriched with bioactive compounds in spontaneously hypertensive rats. Nutrients 2019, 11, 1728.
[CrossRef] [PubMed]
126. Tomizawa, H.; Matsuzawa, D.; Ishii, D.; Matsuda, S.; Kawai, K.; Mashimo, Y.; Sutoh, C.; Shimizu, E.
Methyl-donor deficiency in adolescence affects memory and epigenetic status in the mouse hippocampus.
Genes Brain Behav. 2015, 14, 301–309. [CrossRef] [PubMed]
127. Jia, L.; Li, J.; He, B.; Jia, Y.; Niu, Y.; Wang, C.; Zhao, R. Abnormally activated one-carbon metabolic pathway
is associated with mtdna hypermethylation and mitochondrial malfunction in the oocytes of polycystic gilt
ovaries. Sci. Rep. 2016, 6, 19436. [CrossRef]
128. Clare, C.E.; Brassington, A.H.; Kwong, W.Y.; Sinclair, K.D. One-carbon metabolism: Linking nutritional
biochemistry to epigenetic programming of long-term development. Annu. Rev. Anim. Biosci. 2019, 7,
263–287. [CrossRef]
129. Ibáñez, L.; de Zegher, F. Polycystic ovary syndrome in adolescent girls. Pediatr. Obes. 2020, 15, e12586.
[CrossRef]
130. Xu, N.; Kwon, S.; Abbott, D.H.; Geller, D.H.; Dumesic, D.A.; Azziz, R.; Guo, X.; Goodarzi, M.O. Epigenetic
mechanism underlying the development of polycystic ovary syndrome (pcos)-like phenotypes in prenatally
androgenized rhesus monkeys. PLoS ONE 2011, 6, e27286. [CrossRef]
131. Nilsson, E.E.; Sadler-Riggleman, I.; Skinner, M.K. Environmentally induced epigenetic transgenerational
inheritance of disease. Environ. Epigenet. 2018, 4, dvy016. [CrossRef]
132. Abbott, D.H.; Dumesic, D.A.; Levine, J.E. Hyperandrogenic origins of polycystic ovary
syndrome—Implications for pathophysiology and therapy. Expert Rev. Endocrinol. Metab. 2019, 14,
131–143. [CrossRef]
133. Zhang, D.; Cong, J.; Shen, H.; Wu, Q.; Wu, X. Genome-wide identification of aberrantly methylated promoters
in ovarian tissue of prenatally androgenized rats. Fertil. Steril. 2014, 102, 1458–1467. [CrossRef]
134. Sinha, N.; Roy, S.; Huang, B.; Wang, J.; Padmanabhan, V.; Sen, A. Developmental programming: Prenatal
testosterone-induced epigenetic modulation and its effect on gene expression in sheep ovary†. Biol. Reprod.
2020, 102, 1045–1054. [CrossRef] [PubMed]
135. Lei, L.; Ding, L.; Su, J.; Liu, M.; Shi, Q.; Zhou, J.; Sun, H.; Yan, G. Attenuated expression of mtr in both prenatally
androgenized mice and women with the hyperandrogenic phenotype of pcos. PLoS ONE 2017, 12, e0187427.
[CrossRef]
136. Lambertini, L.; Saul, S.R.; Copperman, A.B.; Hammerstad, S.S.; Yi, Z.; Zhang, W.; Tomer, Y.; Kase, N.
Intrauterine reprogramming of the polycystic ovary syndrome: Evidence from a pilot study of cord blood
global methylation analysis. Front. Endocrinol. 2017, 8, 352. [CrossRef]
137. Echiburú, B.; Milagro, F.; Crisosto, N.; Pérez-Bravo, F.; Flores, C.; Arpón, A.; Salas-Pérez, F.; Recabarren, S.E.;
Sir-Petermann, T.; Maliqueo, M. DNA methylation in promoter regions of genes involved in the reproductive
and metabolic function of children born to women with pcos. Epigenetics 2020, 1–17. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8211 20 of 20
138. Risal, S.; Pei, Y.; Lu, H.; Manti, M.; Fornes, R.; Pui, H.; Zhao, Z.; Massart, J.; Ohlsson, C.; Lindgren, E.; et al.
Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat. Med.
2019, 25, 1894–1904. [CrossRef]
139. Oostingh, E.C.; Koster, M.P.H.; van Dijk, M.R.; Willemsen, S.P.; Broekmans, F.J.M.; Hoek, A.; Goddijn, M.;
Klijn, N.F.; van Santbrink, E.J.P.; Steegers, E.A.P.; et al. First effective mhealth nutrition and lifestyle coaching
program for subfertile couples undergoing in vitro fertilization treatment: A single-blinded multicenter
randomized controlled trial. Fertil. Steril. 2020. [CrossRef]
140. Oostingh, E.C.; Hall, J.; Koster, M.P.H.; Grace, B.; Jauniaux, E.; Steegers-Theunissen, R.P.M. The impact
of maternal lifestyle factors on periconception outcomes: A systematic review of observational studies.
Reprod. Biomed. Online 2019, 38, 77–94. [CrossRef]
141. Van der Windt, M.; van der Kleij, R.M.; Snoek, K.M.; Willemsen, S.P.; Dykgraaf, R.H.M.; Laven, J.S.E.;
Schoenmakers, S.; Steegers-Theunissen, R.P.M. Impact of a blended periconception lifestyle care approach
on lifestyle behaviors: Before-and-after study. J. Med. Internet Res. 2020, 22, e19378. [CrossRef] [PubMed]
142. Lee, I.; Cooney, L.G.; Saini, S.; Smith, M.E.; Sammel, M.D.; Allison, K.C.; Dokras, A. Increased risk
of disordered eating in polycystic ovary syndrome. Fertil. Steril. 2017, 107, 796–802. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
